Curriculum vitae for Keith Davis
As director of the IU Biotechnology Program, Keith Davis relies upon his years of broad-based academic and industry experience in developing and managing research programs in biotechnology that utilized functional genomics and systems biology approaches for target discovery and accelerating R & D.
In addition to overseeing the Biotechnology Program, Davis serves as the Director of Faculty Engagement for the Innovation and Commercialization Office at IU Bloomington. He came to IU Bloomington in 2014 as the first director of the Johnson Center for Entrepreneurship in Biotechnology, a position designed to assist faculty at IU Bloomington’s College of Arts and Sciences in the commercialization of research discoveries.
Before IU, Davis was the founding Executive Director of the Owensboro Cancer Research Program, a satellite program of the University of Louisville James Graham Brown Cancer focused on using plant-based systems for the development of biologics for infectious disease and cancer, and Professor in the Department of Pharmacology and Toxicology. From July 1999 to June 2005, Keith worked at Icoria, Inc. (formerly Paradigm Genetics, Inc.), a biotechnology located in Research Triangle Park that used systems biology platforms for large R&D projects in both the agricultural biotechnology and health sectors. He served as Vice President for Agricultural Biotechnology at Icoria from April 2002 to June 2005 and led the transition team after his business unit was acquired by Monsanto. Before joining Icoria, Davis was a tenured Associate Professor in the Department of Plant Biology at The Ohio State University, where he also served as the director of the campuswide Plant Biotechnology Program.
Honors and awards
Phi Beta Kappa
Beta Beta Beta
Davis's research focuses on plant-made pharmaceutical R&D and translational research in cancer biology. More specifically, he studies the development of the soy-derived peptide, Lunasin, as a cancer chemoprevention agent and therapeutic and the use of pharmacologic doses of ascorbic acid as an adjuvant treatment to enhance cancer therapies.